TORNTPHARM Torrent Pharmaceuticals Q2 FY27 results (Jul–Sep 2026) and concall
Management summary
- Torrent Pharma delivered strong Q2 FY27 results with consolidated revenue advancing 51% YoY to ₹4,979 crores and EBITDA rising 54% YoY to ₹1,666 crores, aided by the merger of JB effective July 8, 2026.
- The base India branded business outperformed industry growth at 20% YoY, supported by new launches and Curatio's 34% growth.
- While transient integration disruptions impacted JB's international business and Germany faced structural pricing headwinds, management expects overall JB growth to rebound to double digits in H2 FY27 and cost synergies to materialize ahead of the original three-year sche
Source: Inve concall analysis and management guidance record.
Highlights
-
Consolidated revenues grew 51% YoY to ₹4,979 crores and operating EBITDA grew 54% YoY to ₹1,666 crores
-
Torrent base India business recorded 20% YoY growth to ₹2,181 crores versus IPM growth of 12%
-
Curatio business maintained strong momentum, growing 34% in Q2 and H1, and now contributes 7-8% of base India sales
-
Cost synergies tracking ahead of schedule, with about half of the ₹450 crore target expected to be realized in FY27 and full realization in 2 years instead of 3
What they filed
Q2 FY27: revenue up 50.1%, net profit down 16.6% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,377 | 2,433 | 2,616 | 2,762 | 2,599 +9% | 3,445 +42% | 4,158 +59% | 4,145 +50% |
| EBITDA | 887 | 868 | 979 | 1,072 | 1,000 +13% | 1,228 +41% | 1,573 +61% | 1,571 +47% |
| Net profit | 485 | 474 | 551 | 597 | 577 +19% | 309 −35% | 492 −11% | 498 −17% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Profitability
JB Cost Synergies Target Profitability · next 2 years · High confidence ₹450 crores
Margin
Consolidated EBITDA Margin Margin · H2 FY27 · Medium confidence Higher than 33.5%
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2JB EBITDA Margin Quantification & Sequential Delta Evasive
No, that's something which we are not guiding for... What we said is the R&D expenses versus quarter one has gone up by 0.7%. Quarter 1, the overall EBITDA margin was 33.8, and this time, it's 33.5.
Management refused to quantify the exact sequential margin improvement or absolute margin for JB, citing only higher overall R&D spend and directional gains from field force rationalization.
Asked by Dr. Kunal Dhamesha (Macquarie Capital)
Synergy Timeline Acceleration and Potential Upside Beyond ₹450 Crores Direct
We believe most of it could come through by the next year... Instead of three years, I think we should be able to get there in two years' time. And any upside to that, I think we'd wait for at least a couple more quarters.
Confirms cost synergies are delivering ahead of schedule, with half already reflected in FY27 margins and full execution compressed from 3 years into 2 years.
Asked by Neha Manpuria (Bank of America)
Unlock risks & concerns, Q3 FY27 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 7 risks, concerns & management red flags
- 4 watchlist triggers for Q3 FY27
- +9 more guidance targets & verbatim management quotes
- +6 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





